Loading company…
Pyrotech develops drug research platforms and candidate treatments for cancer, inflammatory, and other diseases.
Founded in 2020 and based in Beijing, China, Pyrotech provides pharmaceutical R&D and manufacturing services, with R&D centers in Beijing and Shanghai and business development and clinical centers in the US. Its platforms focus on small molecule immunomodulators, pyroptosis regulation, and disease translation, with programs for cancer, hereditary disease, sepsis, kidney damage, and asthma. In July 2026, it raised pre-Series B funding led by Shanghai State-owned Capital Investment Leading Fund, with Zhongguancun Science City Capital, Shanghai Minhang Financial Investment Development, Septwolves Holding, China Reform Holdings, Shunxi Fund, Green Waters Fund, Frees Fund, Changkejin Investment, Lccap, and other investors participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in